Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

0.8803 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
Enveric Stock Soars On Reception Of Notice Of Allowance For Patent Application For Its Psilocin Prodrug Designs
Enveric Biosciences, Inc. 
Via Benzinga
Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug
From Enveric Biosciences, Inc.
Via Business Wire
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?
Enveric Biosciences’ Notice of Allowance for a therapeutic patent is bolstering ENVB stock, but investors should exercise caution. 
Via InvestorPlace
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share. 
Via Benzinga
Enveric Releases Paper Detailing The Development Of Novel Psilocin Prodrugs For The Treatment Of Mental Health Disorders
Enveric Biosciences, Inc. (NASDAQ: ENVB) has announced new research results detailing the development of novel psilocin prodrug derivatives targeting treatment of mental health disorders. A manuscript... 
Via Benzinga
Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders
From Enveric Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why DXC Technology Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket
Gainers Monogram Orthopaedics Inc. (NASDAQ: MGRM) shares surged 163.7% to $30.98 in pre-market trading after jumping 62% on Thursday. Monogram Orthopaedics raised $17,216,147 through the sale of... 
Via Benzinga
Enveric Biosciences to Participate in 2023 BIO International Convention in Boston
From Enveric Biosciences, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start off the final day of the trading week with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Dow Tumbles 150 Points; Alibaba Earnings Top Views
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 150 points on Thursday. The Dow traded down 0.48% to 33,259.03 while the NASDAQ rose 0.63% to 12,579.41. The S&P... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Monro Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers CaliberCos Inc. (NASDAQ: CWD) shares jumped 65.6% to $9.94 amid post-IPO volatility. 
Via Benzinga
Enveric Biosciences Inc. (NASDAQ: ENVB) is One of Thursday Morning’s Most Active Stocks
Via Investor Brand Network
Nasdaq Surges 100 Points; Walmart Raises Full-Year Outlook
U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.09% to 33,451.95 while the NASDAQ rose 0.79% to 12,599.66. The S&P... 
Via Benzinga
Enveric Biosciences (NASDAQ: ENVB) Obtains Notice of Allowance For a U.S. Patent Covering Its Innovative Psilocin Prodrug, EB-373
Enveric Biosciences, Inc. (NASDAQ: ENVB) is engaged as a biotechnology company, which focused on the research and development of innovative 
Via Spotlight Growth
Topics Derivatives Intellectual Property
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Enveric Biosciences Receives Notice Of Allowance From US Patent And Trademark Office For Novel Prodrug Of Psilocin
Enveric Biosciences, Inc. (NASDAQ: ENVB) has received a notice of allowance from the United States Patent and Trademark Office for a patent application involving EB-373, th 
Via Benzinga
Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Q1 Net Loss Of $4.80M, More On Basic And Diluted Loss Per Share
Enveric Biosciences, Inc. (NASDAQ: ENVB) released its corporate update and reported financial results for the first quarter of 2023 ending March 31, 2023. 
Via Benzinga
Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month
From Enveric Biosciences, Inc.
Via Business Wire
EXCLUSIVE: Fireside With Enveric Biosciences's Dr. Tucker, Unlocking Psychedelic Healing Benefits
Recently, at the Benzinga Psychedelic Capital Conference, leading experts from the biotech and pharmaceutical industry gathered to discuss the remarkable potential of psychedelics in medicine. 
Via Benzinga
EXCLUSIVE: Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutionizing psychedelic therapy as a promising new approach for treating mental... 
Via Benzinga
Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
From Enveric Biosciences, Inc.
Via Business Wire
What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey. 
Via Benzinga
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.